Table 2.
Characteristics and medication of CD patients.
| Age | Disease duration (years) | Montreal Classification | HBI | SES-CD Score | CD endoscopic activity | WBC (x103/L) | CRP (mg/L) | Calprotectin (µg/g) | BMI (kg/m2) | Current IBD specific therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| 33 | 10 | A2L3B2 | 0 | 17 | severe | 9.3 | 9.7 | 1416 | 21.7 | vedolizumab |
| 50 | 5 | A2L2B3p | 3 | 0 | inactive | 7.87 | 6.6 | <20 | 27.9 | none |
| 42 | nd | A3L1B1 | 0 | 7 | mild | 10.06 | 7.2 | 872 | 25.2 | mesalamine |
| 33 | 10 | A2L2B2 | 1 | 12 | moderate | 8.59 | 4.1 | 826 | 29.4 | none |
| 22 | 0.5 | A2L3B2 | 4 | 24 | severe | 9.66 | 55.8 | 980 | 21.5 | steroids, antibiotics |
| 25 | 7 | A2L4 + B1 | 2 | 0 | inactive | 9.98 | <0.6 | 24 | 22.2 | infliximab |
| 44 | 6 | A2L3B3 | 3 | 5 | mild | 10.26 | 9.9 | 284 | 18.9 | adalimumab |
| 35 | 16 | A2L3B2 | 2 | 7 | mild | 5.33 | 3.5 | 155 | 27.4 | adalimumab |
| 46 | 3 | A1L4 + B3p | 0 | 3 | inactive | 6.09 | 2.1 | 938 | 20.9 | infliximab |
| 40 | 15 | A2L1B2 | 4 | 3 | inactive | 3.56 | 0.7 | 60 | 24.2 | antibiotics |
| 36 | 11 | A2L2B1 | 5 | 9 | mild | 8.85 | 3.6 | 2345 | 19.4 | AZA |
| 49 | 20 | A2L1B2 | 0 | 6 | mild | 2.69 | <0.6 | 240 | 19.8 | AZA, adalimumab |
| 43 | 0.7 | A2L3B1 | 7 | 26 | severe | 14.45 | 49.5 | <20 | 27.5 | AZA, steroids, mesalamine |
| 52 | 6 | A2L3B3p | 0 | 0 | inactive | 5.49 | 1.9 | <20 | 20.1 | cholestyramine |
| 54 | 28 | A2L2B1 | 7 | 10 | mild | 5.74 | 2.8 | 196 | 2713 | mesalamine, adalimumab, AZA |
AZA, azathioprine; CRP, C-reactive protein; HBI, Harvey-Bradshaw Index; BMI, body mass index; nd, newly diagnosed; na, not applied; SES-CD, Simple Endoscopic Score for Crohn’s Disease; WBC, white blood cell count.